Table of Contents
Table of Contents 2
List of Tables 14
List of Figures 18
Introduction 19
Global Markets Direct Report Coverage 19
Ovarian Cancer Overview 20
Therapeutics Development 21
An Overview of Pipeline Products for Ovarian Cancer 21
Ovarian Cancer Therapeutics under Development by Companies 23
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 42
Comparative Analysis 42
Mid Clinical Stage Products 43
Comparative Analysis 43
Early Clinical Stage Products 44
Comparative Analysis 44
Discovery and Pre-Clinical Stage Products 45
Comparative Analysis 45
Companies Involved in Ovarian Cancer Therapeutics Development 46
Bristol-Myers Squibb Company 46
Genzyme Corporation 46
Abraxis BioScience, Inc. 47
Johnson & Johnson 47
Boehringer Ingelheim GmbH 48
F. Hoffmann-La Roche Ltd. 48
Abbott Laboratories 49
AlphaRx, Inc. 49
Amgen Inc. 50
Sanofi-Aventis 50
AstraZeneca PLC 51
Eli Lilly and Company 52
Viralytics Ltd. 53
GlaxoSmithKline plc 53
Bioniche Life Sciences, Inc. 54
Nektar Therapeutics 54
GenVec, Inc. 55
Daiichi Sankyo Company, Ltd 55
Merck & Co., Inc. 56
FASgen, Inc. 56
Micromet, Inc. 57
Myriad Genetics, Inc. 57
Novo Nordisk A/S 58
Generex Biotechnology Corporation 58
Takeda Pharmaceutical Company Limited 59
MediGene AG 59
Prolexys Pharmaceuticals, Inc. 60
Bio-Path Holdings, Inc. 60
ZIOPHARM Oncology, Inc. 61
Millennium Pharmaceuticals, Inc. 61
Novartis AG 62
Samyang Corporation 62
Aphios Corporation 63
Astellas Pharma Inc. 63
Eisai Co., Ltd. 64
ImmunoGen, Inc. 64
Pfizer Inc. 65
Sigma-Tau S.p.A. 65
Sunesis Pharmaceuticals, Inc. 66
Cell Therapeutics, Inc. 66
Sun Pharmaceutical Industries Limited 67
Santaris Pharma A/S 67
Exelixis, Inc. 68
Aduro BioTech 68
Menarini Group 69
Bayer AG 69
Merck KGaA 70
Access Pharmaceuticals, Inc. 70
Advaxis, Inc. 71
EntreMed, Inc. 71
Hana Biosciences, Inc. 72
Celldex Therapeutics, Inc. 72
ValiRx Plc 73
AEterna Zentaris Inc. 73
ImmunoCellular Therapeutics, Ltd. 74
Insmed Incorporated 74
Lpath, Inc. 75
AVAX Technologies, Inc. 75
Northwest Biotherapeutics, Inc. 76
Novelos Therapeutics, Inc. 76
Novogen Limited 77
ChemGenex Pharmaceuticals Limited 77
Oncolytics Biotech Inc. 78
Oncothyreon Inc 78
Patrys Limited 79
Critical Outcome Technologies Inc. 79
ARQULE, INC 80
Alnylam Pharmaceuticals, Inc 80
Cytokinetics, Inc 81
Telik, Inc. 81
TopoTarget A/S 82
Legacy Health System 82
CytRx Corporation 83
Poniard Pharmaceuticals, Inc. 83
Regeneron Pharmaceuticals, Inc. 84
Oncogenex Pharmaceuticals, Inc. 84
Pharmacyclics, Inc. 85
Dendreon Corporation 85
Thallion Pharmaceuticals Inc. 86
PharmaGap Inc. 86
Quest PharmaTech Inc. 87
Synta Pharmaceuticals Corp. 87
Clavis Pharma ASA 88
Oasmia Pharmaceutical AB 88
Algeta ASA 89
Protox Therapeutics Inc. 89
Rexahn Pharmaceuticals, Inc. 90
Baylor College of Medicine 90
Oryzon 91
Debiopharm Group 91
Actar AB 92
Supratek Pharma Inc. 92
GANYMED Pharmaceuticals AG 93
Abiogen Pharma S.p.A. 93
Glycotope GmbH 94
TRION Pharma GmbH 94
BioNumerik Pharmaceuticals, Inc. 95
Indena S.p.A. 95
Alethia Biotherapeutics Inc. 96
Heat Biologics, Inc. 96
MacroGenics, Inc. 97
Fresenius Biotech GmbH 97
Azaya Therapeutics, Inc. 98
CanBas Co., Ltd. 98
Pivotal BioSciences, Inc. 99
Spirogen Ltd. 99
Neotropix, Inc. 100
Conatus Pharmaceuticals Inc. 100
CritiTech, Inc. 101
Rottapharm SpA 101
Jennerex Biotherapeutics, Inc. 102
BioCancell Therapeutics, Inc. 102
Endocyte, Inc. 103
Onconova Therapeutics, Inc 103
MolMed S.p.A. 104
Pharminox Limited 104
OncoMune, LLC 105
Immunotope, Inc. 105
Esperance Pharmaceuticals, Inc. 106
Expression Genetics, Inc. 106
ImmunoVaccine Technologies Inc. 107
Welichem Biotech Inc. 107
Angstrom Pharmaceuticals, Inc. 108
Vaccinogen, Inc. 108
Cancer Vaccines Limited 109
Quintessence Biosciences, Inc. 109
Viventia Biotechnologies Inc. 110
ViRexx Medical Corp. 110
AstraZeneca AB 111
Advanced Cancer Therapeutics 111
Oncolix, Inc. 112
Eagle Pharmaceuticals Inc 112
British Canadian Biosciences Corp. 113
RECEPTA Biopharma S.A. 113
Mebiopharm Co., Ltd. 114
Theradex Systems, Inc. 114
Immunovative Therapies, Ltd. 115
Hoosier Oncology Group, Inc. 115
Accelerated Community Oncology Research Network, Inc. 116
Kyowa Hakko USA, Inc. 116
Universities/Institutes Involved in Ovarian Cancer Therapeutics Development 117
Ovarian Cancer Therapeutics Assessment 151
Assessment by Monotherapy Products 151
Assessment by Combination Products 152
Assessment by Route of Administration 153
Assessment by Molecule Type 155
Late Stage Drug Profiles – Companies 157
Abagovomab - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
Arzoxifene - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
Avastin - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Avastin + Paclitaxel + Topotecan + Liposomal doxorubicin - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
EPO906 - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Karenitecin - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
MORAb-003 - Drug Profile 164
Product Description 164
Mechanism of Action 164
R&D Progress 164
OPAXIO - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 165
Paclical - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
Particulate Delivery - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
Phenoxodiol + Carboplatin - Drug Profile 168
Product Description 168
Mechanism of Action 168
R&D Progress 168
Recentin - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
TELCYTA - Drug Profile 171
Product Description 171
Mechanism of Action 171
R&D Progress 171
Telcyta + Pegylated Liposomal Doxorubicin - Drug Profile 172
Product Description 172
Mechanism of Action 172
R&D Progress 172
TNF-Alpha - Drug Profile 174
Product Description 174
Mechanism of Action 174
R&D Progress 174
Votrient - Drug Profile 175
Product Description 175
Mechanism of Action 175
R&D Progress 175
Late Stage Drug Profiles – Universities/Institutes 176
Altretamine + Cisplatin + Cyclophosphamide - Drug Profile 176
Product Description 176
Mechanism of Action 176
R&D Progress 176
Amifostine Trihydrate for Ovarian Epithelial Cancer (Robert H. Lurie Cancer Center) - Drug Profile 177
Product Description 177
Mechanism of Action 177
R&D Progress 177
bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug Profile 178
Product Description 178
Mechanism of Action 178
R&D Progress 179
Bevacizumab + Carboplatin + Docetaxel/Paclitaxel - Drug Profile 181
Product Description 181
Mechanism of Action 181
R&D Progress 181
Bevacizumab + Carboplatin + Paclitaxel - Drug Profile 182
Product Description 182
Mechanism of Action 182
R&D Progress 182
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile 184
Product Description 184
Mechanism of Action 184
R&D Progress 185
Carboplatin - Drug Profile 186
Product Description 186
Mechanism of Action 186
R&D Progress 186
Carboplatin + Cisplatin - Drug Profile 187
Product Description 187
Mechanism of Action 187
R&D Progress 187
carboplatin + cisplatin + cyclophosphamide + doxorubicin - Drug Profile 188
Product Description 188
Mechanism of Action 188
R&D Progress 189
carboplatin + cisplatin + cyclophosphamide + doxorubicin hydrochloride + paclitaxel - Drug Profile 190
Product Description 190
Mechanism of Action 190
R&D Progress 191
Carboplatin + Gemcitabine - Drug Profile 192
Product Description 192
Mechanism of Action 192
R&D Progress 192
Carboplatin + Gemcitabine - Drug Profile 193
Product Description 193
Mechanism of Action 193
R&D Progress 193
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 195
Product Description 195
Mechanism of Action 195
R&D Progress 195
carboplatin + gemcitabine hydrochloride - Drug Profile 197
Product Description 197
Mechanism of Action 197
R&D Progress 197
carboplatin + gemcitabine hydrochloride + paclitaxel - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 199
carboplatin + glutathione + paclitaxel - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 200
Carboplatin + Ifosfamide - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
Carboplatin + Ifosfamide + Whole-Body Hyperthermia - Drug Profile 203
Product Description 203
Mechanism of Action 203
R&D Progress 203
Carboplatin + Liposomal Doxorubicin - Drug Profile 205
Product Description 205
Mechanism of Action 205
R&D Progress 205
carboplatin + mitoxantrone + cyclophosphamide + stem cell transplantation - Drug Profile 206
Product Description 206
Mechanism of Action 206
R&D Progress 207
Carboplatin + Paclitaxel - Drug Profile 208
Product Description 208
Mechanism of Action 208
R&D Progress 208
Carboplatin + Paclitaxel - Drug Profile 209
Product Description 209
Mechanism of Action 209
R&D Progress 209
Carboplatin + Paclitaxel - Drug Profile 211
Product Description 211
Mechanism of Action 211
R&D Progress 211
Carboplatin + Paclitaxel - Drug Profile 212
Product Description 212
Mechanism of Action 212
R&D Progress 212
carboplatin + paclitaxel + bevacizumab - Drug Profile 214
Product Description 214
Mechanism of Action 214
R&D Progress 215
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 216
Product Description 216
Mechanism of Action 216
R&D Progress 216
Carboplatin + Paclitaxel + Bevacizumab_ - Drug Profile 217
Product Description 217
Mechanism of Action 217
R&D Progress 217
Carboplatin + Paclitaxel + Cediranib - Drug Profile 218
Product Description 218
Mechanism of Action 218
R&D Progress 218
Carboplatin + Paclitaxel + Doxorubicin HCl Liposome - Drug Profile 220
Product Description 220
Mechanism of Action 220
R&D Progress 220
Carboplatin + Paclitaxel + Gemcitabine - Drug Profile 222
Product Description 222
Mechanism of Action 222
R&D Progress 222
Carboplatin + Paclitaxel + Topotecan - Drug Profile 224
Product Description 224
Mechanism of Action 224
R&D Progress 224
Carboplatin + Paclitaxel + Topotecan - Drug Profile 226
Product Description 226
Mechanism of Action 226
R&D Progress 226
Carboplatin + Paclitaxel + Topotecan Hydrocholride - Drug Profile 228
Product Description 228
Mechanism of Action 228
R&D Progress 228
carboplatin + pegylated liposomal doxorubicin hydrochloride - Drug Profile 230
Product Description 230
Mechanism of Action 230
R&D Progress 230
Carboplatin + Taxol - Drug Profile 232
Product Description 232
Mechanism of Action 232
R&D Progress 232
Carboplatin + Taxol - Drug Profile 233
Product Description 233
Mechanism of Action 233
R&D Progress 233
Carboplatin + Topotecan Hydrochloride - Drug Profile 234
Product Description 234
Mechanism of Action 234
R&D Progress 234
cediranib - Drug Profile 235
Product Description 235
Mechanism of Action 235
R&D Progress 235
Cediranib + Cisplatin + Paclitaxel for Overian Cancer (Medical Research Council) - Drug Profile 236
Product Description 236
Mechanism of Action 236
R&D Progress 236
Cisplatin + Adriamycin - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
Cisplatin + Carboplatin - Drug Profile 239
Product Description 239
Mechanism of Action 239
R&D Progress 239
Cisplatin + Paclitaxel - Drug Profile 240
Product Description 240
Mechanism of Action 240
R&D Progress 240
Cisplatin + Taxol - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
Cisplatin + Taxol - Drug Profile 242
Product Description 242
Mechanism of Action 242
R&D Progress 242
Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile 243
Product Description 243
Mechanism of Action 243
R&D Progress 244
Doxorubicin + Carboplatin - Drug Profile 245
Product Description 245
Mechanism of Action 245
R&D Progress 245
erlotinib hydrochloride - Drug Profile 246
Product Description 246
Mechanism of Action 246
R&D Progress 246
Gemcitabine - Drug Profile 247
Product Description 247
Mechanism of Action 247
R&D Progress 247
Gemcitabine + Cisplatin - Drug Profile 248
Product Description 248
Mechanism of Action 248
R&D Progress 248
Ifosfamide + Paclitaxel - Drug Profile 250
Product Description 250
Mechanism of Action 250
R&D Progress 250
Irinotecan + Cisplatin - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 251
Irinotecan + Cisplatin - Drug Profile 252
Product Description 252
Mechanism of Action 252
R&D Progress 252
Irinotecan + Cisplatin - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
levofloxacin - Drug Profile 254
Product Description 254
Mechanism of Action 254
R&D Progress 254
levofloxacin - Drug Profile 255
Product Description 255
Mechanism of Action 255
R&D Progress 255
Liposomal Doxorubicin - Drug Profile 256
Product Description 256
Mechanism of Action 256
R&D Progress 256
OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile 257
Product Description 257
Mechanism of Action 257
R&D Progress 257
Oxaliplatin + Capecitabine - Drug Profile 258
Product Description 258
Mechanism of Action 258
R&D Progress 258
Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 259
Product Description 259
Mechanism of Action 259
R&D Progress 259
Paclitaxel - Drug Profile 260
Product Description 260
Mechanism of Action 260
R&D Progress 260
Paclitaxel - Drug Profile 261
Product Description 261
Mechanism of Action 261
R&D Progress 261
Paclitaxel + Carboplatin - Drug Profile 262
Product Description 262
Mechanism of Action 262
R&D Progress 262
Paclitaxel + Carboplatin - Drug Profile 263
Product Description 263
Mechanism of Action 263
R&D Progress 263
Paclitaxel + Carboplatin - Drug Profile 264
Product Description 264
Mechanism of Action 264
R&D Progress 264
Paclitaxel + Carboplatin - Drug Profile 265
Product Description 265
Mechanism of Action 265
R&D Progress 265
Paclitaxel + Carboplatin + Bevacizumab - Drug Profile 266
Product Description 266
Mechanism of Action 266
R&D Progress 266
Paclitaxel + Saracatinib - Drug Profile 267
Product Description 267
Mechanism of Action 267
R&D Progress 267
Paclitaxel+Carboplatin - Drug Profile 268
Product Description 268
Mechanism of Action 268
R&D Progress 268
Sertraline + Haloperidol - Drug Profile 269
Product Description 269
Mechanism of Action 269
R&D Progress 269
Sodium Thiosulfate - Drug Profile 270
Product Description 270
Mechanism of Action 270
R&D Progress 270
stealth liposomal doxorubicin + carboplatin + paclitaxel - Drug Profile 271
Product Description 271
Mechanism of Action 271
R&D Progress 271
testosterone - Drug Profile 273
Product Description 273
Mechanism of Action 273
R&D Progress 273
Tirazone - Drug Profile 274
Product Description 274
Mechanism of Action 274
R&D Progress 274
Topotecan - Drug Profile 275
Product Description 275
Mechanism of Action 275
R&D Progress 275
Treosulfan - Drug Profile 276
Product Description 276
Mechanism of Action 276
R&D Progress 276
Treosulfan - Drug Profile 277
Product Description 277
Mechanism of Action 277
R&D Progress 277
Discontinued Products 278
Ovarian Cancer - Featured News 279
Dec 14, 2010: Immunovaccine Reports Preliminary Safety Results From Phase I Cancer Vaccine Trial 279
Dec 13, 2010: EGEN Begins EGEN-001 Phase II Clinical Trial For Advanced Ovarian Cancer 279
Dec 07, 2010: Aduro BioTech Presents Clinical Results From CRS-207 Phase I Trial At AACR Special Conference 280
Dec 02, 2010: BioMarin Receives Notice Of Acceptance From MHRA For BMN 673 For Genetically-Defined Cancers 280
Nov 18, 2010: Marshall Edwards Announces Presentation Of New Data Showing Activity In Chemotherapy-Resistant Ovarian Cancer Cells 280
Nov 18, 2010: Exelixis Reports Promising Phase II Interim Data Of XL184 In Ovarian Cancer 281
Nov 17, 2010: Immunovaccine Announces Phase I/II Clinical Plan For DPX-Survivac To Target Ovarian Cancer 282
Nov 15, 2010: Sunesis Receives US Patent Covering Vosaroxin Clinical Formulation 282
Nov 03, 2010: Access Commences ProLindac Phase II Combination Clinical Trial In Platinum-Sensitive Ovarian Cancer Patients 283
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 284
Appendix 285
Methodology 285
Coverage 285
Secondary Research 285
Primary Research 285
Expert Panel Validation 286
Contact Us 286
Disclaimer 286